ARHGEF11

Across TCGA pan-cancer cohorts, ARHGEF11 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARHGEF11 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ARHGEF11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, ACC, and UCEC are the cancer types where ARHGEF11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.702	0.950	<.001	33	view →
ACC	DFS	Median	All	0.120	0.772	<.001	30	view →
UCEC	DFS	Median	All	0.953	0.601	.001	22	view →
SKCM	DFS	Median	II,III,IV	0.875	0.671	.007	16	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	13	view →
COAD	DFS	Median	II,III,IV	0.193	0.651	.014	6	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
LUAD	OS	Median	All	0.110	0.375	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARHGEF11–BRCA (DFS)

Open the BRCA breakdown →